EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The role of the microbiome in immune checkpoint inhibitor colitis and hepatitis

Thomas Ryan, Sophia Ling, Andrew Trinh, Jonathan P Segal

Best Practice & Research Clinical Gastroenterology · 2024

DOI: 10.1016/j.bpg.2024.101945 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Best Practice & Research Clinical Gastroenterology, 2024. Verfasst von Thomas Ryan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Melbourne, Melbourne, Australia. Electronic address: tplryan1999@gmail.com. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Colitis, Gastrointestinal Microbiome, Hepatitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers Squibb, Dr. Falk Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors have revolutionised management for a variety of different types of malignancies. However, gastrointestinal adverse effects, in particular colitis and hepatitis, are relatively common with up to 30 % of patients being affected. The gut microbiome has emerged as a potential contributor to both the effectiveness of immune checkpoint inhibitors and their side effects. This review will attempt to examine the impact the microbiome has on adverse effects as a result of immune checkpoint inhibitors as well as the potential for manipulation of the microbiome as a form of management for immune mediated colitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemical and Drug Induced Liver InjuryColitisGastrointestinal MicrobiomeHepatitisImmune Checkpoint InhibitorsHumansNeoplasms

Stichwörter der Autor:innen

Immune checkpoint colitisMicrobiome

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Faculty of Medicine, University of Melbourne, Melbourne, Australia. Electronic address: tplryan1999@gmail.com.
  • Department of Gastroenterology, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Faculty of Medicine, University of Melbourne, Melbourne, Australia; Department of Gastroenterology, Peter MacCallum Cancer Centre, Melbourne, Australia.

Förderung

  • Bristol-Myers Squibb
  • Dr. Falk Pharma

Zitieren

APA

Ryan, T., Ling, S., Trinh, A., & Segal, J. P. (2024). The role of the microbiome in immune checkpoint inhibitor colitis and hepatitis. Best Practice & Research Clinical Gastroenterology. https://doi.org/10.1016/j.bpg.2024.101945

Vancouver

Ryan T, Ling S, Trinh A, Segal JP. The role of the microbiome in immune checkpoint inhibitor colitis and hepatitis. Best Practice & Research Clinical Gastroenterology. 2024. doi:10.1016/j.bpg.2024.101945

BibTeX
@article{Ryan2024,
  author = {Ryan, Thomas and Ling, Sophia and Trinh, Andrew and Segal, Jonathan P},
  title = {The role of the microbiome in immune checkpoint inhibitor colitis and hepatitis},
  journal = {Best Practice & Research Clinical Gastroenterology},
  year = {2024},
  doi = {10.1016/j.bpg.2024.101945}
}
Kostenlos starten →